OP020 INHIBITION OF JAK 1/2 AS A POTENTIAL TARGET IN THE TREATMENT OF RECALCITRANT PYODERMA GANGRENOSUM: A CASE REPORT...European Wound Management Association (EWMA) Conference, May 3-5, 2023, Milan, Italy

Aim: Pyoderma Gangrenosum (PG) is a neutrophilic dermatosis that represents a clinical challenge because of the frequent recurrence of the disease. The aim of our work was to evaluate the use of Baricitinib, an oral JAK1/2 inhibitor, as a third-line biologic agent for the treatment of a multi-refrac...

Full description

Bibliographic Details

Published in:	Journal of Wound Management Vol. 24; no. 2; p. 392
Main Authors:	Margiotta, Flavia Manzo, Michelucci, Alessandra, Granieri, Giammarco, Salvia, Giorgia, Janowska, Agata, Romanelli, Marco
Format:	abstract case study proceedings research Journal Article
Published:	Cambridge Publishing Jul2023
Online Access:	View this record in EBSCOhost